Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Volume over 432,000 to cover. Will they come back after the weekend?
Looks like the shorts did some covering @ .598 for the weekend.
TPIV is being heavily shorted they may have pissed off Gardner and he knows how to make it hurt. If the company does find a grant or big Pharma partner it'll burn the shorts off him though.
http://www.otcmarkets.com/stock/TPIV/short-sales
----------------------------Short Sales
------------- Short Interes --------Avg. Volume
Sept 15, 2014 57,570 -19.81 27,993 2.06 No No
Aug 29, 2014 71,790 10.21 16,955 4.23 No No
Aug 15, 2014 65,137 -0.41 27,067 2.41 No No
Jul 31, 2014 65,405 -3.52 16,356 4.00 No No
Jul 15, 2014 67,790 235.59 27,947 2.43 No No
Jun 30, 2014 20,200 533.43 12,777 1.58 No No
Jun 13, 2014 3,189 -67.13 26,763 1.00 No No
May 30, 2014 9,702 80.50 42,988 1.00 No No
May 15, 2014 5,375 30.43 7,435 1.00 No No
Apr 30, 2014 4,121 273.96 5,913 1.00 No No
What's the timeline on patent expiration?
It looks like NEO Will Wait Till 1Qtr 2015 To Launch the Prostate test. They are into the extended time table required to launch the test. The Aug 10Q say's NEO intends to launch the Plasma Prostate Cancer Test in 2015 so I hope that means 1Qtr
It appears they can take 2 years per product;
a “Plasma Prostate Cancer Test”,
a “Pancreatic Cancer Test”,
a “Colon Cancer Test”,
a “Cytogenetic Interpretation System”
a “Flow Cytometry Interpretation System.”
http://www.otcmarkets.com/stock/HDVY/filings
NeoGenomics License
On January 6, 2012, we entered into a Master License Agreement (the “NeoGenomics License”) with NeoGenomics Laboratories, Inc. (“NeoGenomics Laboratories”), a wholly owned subsidiary of NeoGenomics, Inc. (“NeoGenomics”). Pursuant to the terms of the NeoGenomics License, we granted to NeoGenomics Laboratories and its affiliates an exclusive worldwide license to certain of our patents and know-how to use, develop and sell products in the fields of laboratory testing, molecular diagnostics, clinical pathology, anatomic pathology and digital image analysis (excluding non-pathology-related radiologic and photographic image analysis) relating to the development, marketing production or sale of any “Laboratory Developed Tests” or LDTs or other products used for diagnosing, ruling out, predicting a response to treatment, and/or monitoring treatment of any or all hematopoietic and solid tumor cancers excluding cancers affecting the retina and breast cancer. We retain all rights to in-vitro diagnostic (IVD) test kit development.
Upon execution of the NeoGenomics License, NeoGenomics Laboratories paid us $1,000,000 in cash and NeoGenomics issued to us 1,360,000 shares of NeoGenomics’ common stock, par value $0.001 per share, which had a market value of $1,945,000 using the closing price of $1.43 per share for NeoGenomics’ common stock on the OTC Bulletin Board on January 6, 2012. In addition, the NeoGenomics License provides for milestone payments in cash or stock, based on sublicensing revenue and revenue generated from products and services developed as a result of the NeoGenomics License. Milestone payments will be in increments of $500,000 for every $2,000,000 in GAAP revenue recognized by NeoGenomics Laboratories up to a total of $5,000,000 in potential milestone payments. After $20,000,000 in cumulative GAAP revenue has been recognized by NeoGenomics Laboratories, we will receive a royalty of (i) 6.5% (subject to adjustment under certain circumstances) on net revenue generated from all Licensed Uses except for the Cytogenetic Interpretation System and the Flow Cytometry Interpretation System and (ii) a royalty of 50% of net revenue (after the recoupment of certain development and commercialization costs) that NeoGenomics Laboratories derives from any sublicensing arrangements it may put in place for the Cytogenetic Interpretation System and the Flow Cytometry Interpretation System.
NeoGenomics Laboratories agreed to use it best efforts to commercialize certain products within one year of the date of the license, subject to two one-year extensions per product if needed, including a “Plasma Prostate Cancer Test”, a “Pancreatic Cancer Test”, a “Colon Cancer Test”, a “Cytogenetic Interpretation System”, and a “Flow Cytometry Interpretation System.” NeoGenomics is currently under the second of its one-year extension terms of the license.
If NeoGenomics Laboratories has not generated $5 million of net revenue from products, services and sublicensing arrangements within five years, we may, at our option, revoke the exclusivity with respect to any one or more of the initial licensed products, subject to certain conditions.
The Company believes our relationship with NeoGenomics is instrumental in our medical and diagnostic testing development. We further believe the majority, if not all, of our applications in the medical field will be done in conjunction with NeoGenomics.
Plasma Test for Prostate Cancer
NeoGenomics is developing a test for prostate cancer under the direction of Dr. Maher Albitar using the genes patented by HDC. The test is performed on blood plasma and urine rather than only prostate tissue biopsies. NeoGenomics recently announced that a publication has been released regarding Phase I of the test’s development. Additionally, NeoGenomics completed Phase II of the prostate test validation. The results were largely the same as those published regarding Phase I. While further validation work needs to be completed, NeoGenomics continues to be encouraged about the potential for this new test. This test, which uses HDC’s patented technology, is available for ordering for patients who want to participate in NeoGenomics’ ongoing clinical trial agreement. NeoGenomics is planning a full launch of this prostate test in 2015.
Its is today the 10th: Trial will continue to the next predefined patients analysis point of 130 patients, and so on depending on analysis results.
http://ir.stockpr.com/sanuwave/company-news/detail/1094/sanuwave-health-receives-information-from-the-data-monitoring-committee-on-the-dermapace-clinical-trial
Company News
Email Alerts
Tear Sheet
IR Contacts
RSS News Feed
SANUWAVE Health Receives Information From the Data Monitoring Committee on the dermaPACE Clinical Trial
Download PDF
ALPHARETTA, Ga., Sept. 10, 2014 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (OTCQB:SNWV) today announced that the independent Data Monitoring Committee (DMC) has performed an interim analysis on the efficacy results for the first 90 patients in the Phase III supplemental clinical trial using the dermaPACE® for treating diabetic foot ulcers. The DMC has recommended the Company continue enrollment of patients into the study up to the next predefined patient analysis point of 130 patients. The Company has continued to enroll patients while waiting on the 12 week efficacy analysis for the first 90 patients and expects to complete enrollment for the 130 patients by October 31, 2014.
The DMC will perform an analysis on the entire 130 patient population once the patients have completed the twelve week efficacy analysis period. This is expected to be completed in the first quarter of 2015. After their review of the 130 patients, the DMC may recommend: 1) stopping enrollment because the dermaPACE has met the minimum success criteria as compared to sham-control, 2) increasing enrollment to 170 patients which is the next predefined patient analysis point, or 3) stopping the trial due to poor results.
Kevin A. Richardson II, Chairman of the board of directors of SANUWAVE, commented, "We are encouraged with the feedback from the Data Monitoring Committee and look forward to completing enrollment of the next milestone, 130 patients. The dermaPACE, with its novel biologic regenerative effects, holds promise to heal diabetic foot ulcers and increase limb preservation, thus improving quality of life for these patients and their families and significantly easing the economic burden on an overwhelmed healthcare system that cares for these patients. We continue to work towards our ultimate goal of obtaining FDA approval for dermaPACE and commercializing the technology in the U.S. where millions of people suffer from costly and debilitating diabetic foot ulcers."
The goal of the randomized, double-blind, parallel group, sham controlled, multicenter, 24-week clinical trial is to demonstrate that the healing rate of dermaPACE is statistically superior to that of sham at 12 weeks post initial device application. Patients enrolled in the study receive four non-invasive procedures (dermaPACE or sham) during the first two weeks. In addition, up to four additional non-invasive procedures (dermaPACE or sham) are delivered bi-weekly, between weeks 4 and 10. After the 12 week efficacy evaluation, patients are followed for an additional 12 weeks for safety.
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE's portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body's normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, Australia and New Zealand. In the U.S., dermaPACE is currently under the FDA's Premarket Approval (PMA) review process for the treatment of diabetic foot ulcers. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE's shock wave technology for non-medical uses, including energy, water, food and industrial markets.
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company's product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company's ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
For additional information about the Company, visit www.sanuwave.com.
CONTACT: DC Consulting, LLC
407-792-3333
investorinfo@dcconsultingllc.com
Investor Relations
RedChip Companies, Inc.
Mike Bowdoin, Vice President
800-733-2447, ext. 110
mike@redchip.com
SANUWAVE Health, Inc. Logo
Source: SANUWAVE Health, Inc.
Released September 10, 2014
One of the two things I want to find out is how they arrived at $1.5B USD; the other is GDR fees they were collected in Oct/13.
The GDRs are at 1:1 ratio (Mellon Bank Depository),the stock trades for R 0.18 on Bovespa at currant exch. rate, $0.08 USD. Even the currency arbitrage is in GDRs favor.
Trading Bsp:
http://quotes.esignal.com/esignalprod/quote.action?s=OGXP3F-BSP&type=Stock&fromSearch=true
Mellon DR:
http://www.adrbnymellon.com/dr_directory.jsp
My take on How much the present Markets values OGXPY
Undervalued by todays market:
Estimated val. minus Mrkt val.
Estimated value $1.5B - $213M = $1,286,174,000
Court EstimateValue/share
$1.5B /3.23B sh = $0.464
$0.464 x 3.23B sh = $1,498,720,000 almost $1.5B
Ownership post restucture
15% of shares: 484,500,000shares to Common Shareholders.
85% of 3.23B = 2,745,500,000 shares to Debt holders
(It is very likely there will be a Reverse Split under restructure and share reissued according to percentage of ownership.)
Present Market Cap: @ .0622
Total 3,230,000,000 x .0622 = $213,826,000
Common shareholders 15% 484,500,000 x .0662 = $32,073,900
Debt Holders 85% 2,745,500,000 x .0662 = $181,752,100
TOTAL_____________________________$213,826,000
The present Market Cap according to Yahoo finance is :
.0662 x 3.23b =______________________ $214.22Mill
http://finance.yahoo.com/q;_ylt=AhkGTd2YPymVlAsWZS4tukN2NohG;_ylu=X3oDMTBxdGVyNzJxBHNlYwNVSCAzIERlc2t0b3AgU2VhcmNoIDEx;_ylg=X3oDMTBsdWlqampwBGxhbmcDZW4tVVMEcHQDNQR0ZXN0Aw--;_ylv=3;_ylc=X1MDMjE0MjQ3ODk0OARfcgMyBGZyA3VoM19maW5hbmNlX3dlYl9ncwRmcjIDc2EtZ3AEZ3ByaWQDBG5fZ3BzAzEEb3JpZ2luA2ZpbmFuY2UueWFob28uY29tBHBvcwMxBHBxc3RyAwRxdWVyeQNPR1hQWSwEc2FjAzEEc2FvAzE-?p=http%3A%2F%2Ffinance.yahoo.com%2Fq%3Fs%3DOGXPY%26ql%3D0&hspart=att&hsimp=yhs-att_001&type=yahoo_pc_finance&uhb=uhb2&fr=uh3_finance_vert_gs&s=OGXPY
Another interesting fact is the GDRs are at 1:1 ratio (Mellon Bank Depository) and it is trading for R 0.18 on Bovespa = to $0.08 USD. Even the currency arbitrage is in GDRs favor.
The Fees my be a killer , I'll be looking into that.
Trading Bsp:
http://quotes.esignal.com/esignalprod/quote.action?s=OGXP3F-BSP&type=Stock&fromSearch=true
Mellon DR:
http://www.adrbnymellon.com/dr_directory.jsp
I see your approach.
I come at it ,maybe incorrectly, by:
Undervalued by todays market:
Estimated val. minus Mrkt val.
Estimated value $1.5B - $213M = $1,286,174,000 undervalued
Court EstimateValue/share
$1.5B /3.23B sh = $0.464___$0.4018 undervalued
$0.464 x 3.23B sh = $1,498,720,000 almost $1.5B
Ownership post restucture
15% of shares: 484,500,000shares to Common Shareholders.
85% of 3.23B = 2,745,500,000 shares to Debt holders
(It is very likely there will be a Reverse Split under restructure and share reissued according to percentage of ownership.)
Present Market Cap: @ .0622
Total 3,230,000,000 x .0622 = $213,826,000
Common shareholders 15% 484,500,000 x .0662 = $32,073,900
Debt Holders 85% 2,745,500,000 x .0662 = $181,752,100
The present Market Cap according to Yahoo finance is :
.0662 x 3.23b = $214.22Mill
Am I just being hopeful there is something here?.... thank you DrillaHill
http://finance.yahoo.com/q;_ylt=AhkGTd2YPymVlAsWZS4tukN2NohG;_ylu=X3oDMTBxdGVyNzJxBHNlYwNVSCAzIERlc2t0b3AgU2VhcmNoIDEx;_ylg=X3oDMTBsdWlqampwBGxhbmcDZW4tVVMEcHQDNQR0ZXN0Aw--;_ylv=3;_ylc=X1MDMjE0MjQ3ODk0OARfcgMyBGZyA3VoM19maW5hbmNlX3dlYl9ncwRmcjIDc2EtZ3AEZ3ByaWQDBG5fZ3BzAzEEb3JpZ2luA2ZpbmFuY2UueWFob28uY29tBHBvcwMxBHBxc3RyAwRxdWVyeQNPR1hQWSwEc2FjAzEEc2FvAzE-?p=http%3A%2F%2Ffinance.yahoo.com%2Fq%3Fs%3DOGXPY%26ql%3D0&hspart=att&hsimp=yhs-att_001&type=yahoo_pc_finance&uhb=uhb2&fr=uh3_finance_vert_gs&s=OGXPY
I respect and rely on your great analysis on this board and HRT, I am taking a good look at another Oil & Gas play in Brazil and would like you to look it over. It is in Bankruptcy protection and the share price has tanked to $0.068. However, according to the court papers present commom share holders will receive 10% of the restructured company, plus 5% in warrants = 15% of $1.5 Billion appraised amount (equity value) . This appears to be about $0.46 US per share on 3.23 Billion shares. If this true it looks to be of great potential. Thank you for your trouble.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=105867435
http://www.ogx.com.br/conteudo_en.asp?idioma=1&conta=44&tipo=50977
PS: I bought DYN under similar circumstances and receive warrants and shares. It was a good trade.
Too many zeros 3.23B : 3,230,000,000 shares. It still looks like a value of $0.46/share.
I see there are 323,000,000,000 shares OS and the Court has the company valued at $1.5 billion US, that's $0.46 a share. If this is true were looking at a great upside sleeper here.
The company is looking to work over some wells to increase production, also two other fields will begin to be exploited 2015/2016.
Thanks BVE. I've been going over the 2nd Qtr financials, dated 8/14/14, found some interesting things:
!(Warrant divy for present shareholders)
!(2.4 million bb oil sold 1st half 2014)
!(appraised amount(equity value) of the restructured company of US$1.5 billion )
http://www.ogx.com.br/conteudo_en.asp?idioma=1&conta=44&tipo=50977
2. Restructuring of debts: In addition to obtaining new funds, it is essential that the Company restructures debt incurred with its general creditors, as well as with post- petition creditors who expressly adhere to the Plan.
The DIP Financing, after certain conditions precedent are fulfilled, will be convertible into shares issued by OGX Petróleo e Gás S.A. which will represent, provided that all stages of the Court-Supervised Reorganization Plan are fully implemented, 65% of the total capital stock of the restructured company. After the conversion of the DIP Financing, OGpar’s creditors will be holders of shares representing 25% of the total capital stock of the restructured company.The Company’s current shareholders, after the dilution resulting from the conversion of the credits into capital, including the DIP Financing, will remain holders of shares representing, in the aggregate, 10% of the total capital stock of the restructured company. Additionally, the current shareholders will receive subscription warrants of the restructured company with the following main conditions: (i) exercise term of 5 years; and (ii) number of common shares to be subscribed representing, in the aggregate, fifteen percent (15%) of the total capital stock of the restructured company, considering an issue price based on the appraised amount (equity value) of the restructured company of US$1.5 billion.
5.
The restructuring of debts will be effected, provided that certain conditions precedent are fulfilled, by means of conversion of the claims into OGX Petróleo e Gás S.A. capital stock, while the unsecured creditors that wish so may receive the amount of up to R$30,000.00 cash, and the remainder of the claims will be converted into capital stock under the terms and conditions set forth in the Plan.
Net Results
In the first half of 2014, the Company’s net income came to R$516 million, versus losses of R$5.5 million in the same period last year, primarily due to: (i) a production portfolio that is currently focused on the Tubarão Martelo field, which ended the quarter with two producing wells and generated EBITDA of R$141 million; (ii) resumption, in February 2014, of production in the Tubarão Azul field, which contributed with an EBITDA of R$32 million; (iii) gains on foreign exchange variation, especially unrealized, of R$760 million; and (iv) the 43% reduction in general and administrative expenses, with a leaner headcount that is in line with the Company’s needs and a cost reduction program which includes moving to a new office and the renegotiation of agreements with service providers. These impacts were partially offset by: (v) restructuring costs totaling R$52 million; (vi) the constitution of a provision for inventory losses of R$155 million; (vii) the constitution of a provision for contingencies of R$54 million, due to the enforcement, by the ANH, of bank guarantees of the exploratory program of the Cesar Rancheria Basin in Colombia; and (viii) income taxes payable, totaling R$145 million, which were offset with tax losses.
Sales revenues
The sales carried out by the Company over the course of the First Half of 2014 totaled R$ 513 million, corresponding to the sale of 2.4 million barrels of oil.
?
Tubarão Azul Tubarão Martelo T O T AL
R$ mil
127,324 386,468 5 1 3 , 7 9 2
Bbls mil
605 1,788 2 , 3 9 3
R$/bbls US$ / bbls *
211 96 216 98
????(*) Translated into Brazilian Reais (R$) at the closing exchange rate for the 2nd Quarter (US$ 1.00 = R$ 2.2025).
Hi BVE did't catch that news release, but did buy the
dip. Do you know if the money will be used for debt or CapEx?
BVE came across this article @ Seeking Alpha from 2013. It is interesting at the end of the article he considered it a long term play while it was trading at $1.30, with caveats of course. You might want to read comments section.
http://seekingalpha.com/article/1285401-brazils-ogx-petroleo-outlook-as-the-nations-largest-private-e-and-p-operator
Brazil's OGX Petroleo Outlook As The Nation's Largest Private E&P Operator
Mar. 19, 2013 8:25 AM ET | 25 comments | About: Oleo e Gas Participacoes Sa ADR (OGXPY)
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. (More...)
In response to reader interest, I am releasing the recent correspondence between a Seeking Alpha reader and myself regarding OGX Petróleo e Gás Participações S.A. (OTCPK:OGXPY).
March 13 at 3:51pm
Bom Dia! Richard: I have another thought that you might have a interest(knowledge) in ... ? Do you follow OGXPY? As you undoubtedly know this company has been beaten up something terrible. it was $10 - $11 dollars a share a couple of years ago. Now it,s $1.30+ As you know too ... OGX has some fabulous "proven" reserves that should be of value one of these days ...? With your background in O/G ... What's your thoughts on OGXPY? Has Batista lost his magic? Best Regards, Bill
My reply follows ...
Richard Berger March 13 at 11:56pm
Hi Bill,
OGXPY.PK share decline initially was triggered by rumors of health problems for Eike Batista. These rumors were never substantiated and indeed appear to be completely without basis. Nonetheless, the attention they brought to his holdings in his EBX Group of companies, including OGX, has resulted in some longer term effects. OGX is essentially a closely held corporation controlled by Batista directly owning about 67% of the shares and companies under his control holding another 30.6%. This totals a 97.6% ownership controlled by Batista. The company apparently is only public traded to provide Batista a valuation of his asset for his own purposes and in use as pledging as a guarantee against debt he may take on for his own unrelated business activities.
OGX went public in June 2008 with a $R6.7 billion offering (USD $ 3.35 billion at current exchange rates). third quarter 2012 saw the first oil production sales revenue on an average 9.4kboe/d at a price averaging $142/boe. Production will be rapidly increasing in 2013 with one of the 3 wells in its current producing field back online after a 1 month shut-in for submersible pump equipment replacement and the connection of several more completed wells to production. Late 2013 is forecast to begin significant gas sales from the company's 16 completed but currently unconnected wells. On the other hand, oil prices are only averaging $95/barrel now, a significant decrease from the $142/b received in 2012. OGX does not use hedging to lock in future prices and smooth out price fluctuations.
OGX plans $1.2 billion in expenditures for 2013 and only has current assets of $2.5 billion. The company has entered into an agreement with Batista which provides a put option essentially whereby the outside directors of OGX may make a determination that the company needs additional cash and can require Batista to provide up to USD $1 billion through the purchase of new shares at $R 6.30 per share. This agreement remains in effect through April 30, 2014.
This "PUT" agreement creates a drag on the company in that it may be dilutive to existing share hold equity. The size of such dilution is unclear since the strike price is in Brazilian Reals and the funds are in $USD and the exchange rate should the PUT be exercised is unknown (currently about $3.15/share USD).
Several important downward revisions to OGX estimated reserves have also led to large downward moves in the company share prices. These reductions not only lowered enterprise value but also lowered the confidence in continuing and future statements made by the company with regard to foreword looking results.
Most recently, just a few weeks ago, on February 27, 2013 Eike Batista denied rumors that the company was being sold to Petronas, a state-run Malaysian company. The uncertainties in relation to the company knocked down the company's stock prices on the market since then. The language of Batista's denial of these rumors that his stakes in several of his EBX Group are in negotiations to be sold was interesting. In his statement, Batista says that no agreement has been reached to sell all or any part of any of these companies. He significantly ignored denying the rumor that the negotiations themselves have taken place.
So, the key issues with OGXPY are:
1. It is very closely held with less than 2.4% of its shares floated in the open market to non-controlling interest shareholders.
2. This non-controlling percentage may be significantly reduced if the PUT is exercised. At current exchange rate it would result in another 317.5 million shares to controlling-interest holders. This is about 10% of the total outstanding shares.
3. With a current market cap of $ 3.92 billion and enterprise value of $ 6.91 billion, The PUT agreement providing for 10% of the outstanding shares (based on current exchange rates) does not appear to have any likelihood of being dilutive.
4. The PUT agreement price of $R6.70 (USD $3.15 currently) does put a upper limit on market share price if it is to remain non-dilutive.
5. The market appears to place a very low value on the shares due to the high percentage owned by controlling interests (virtually all controlled by Batista). This situation is unlikely to change for the better in the near future. The PUT option in fact would significantly increase the percentage held by Batista.
6. A possible sale by Batista to raise cash for his own goals separate from OGX are a drag on its shares in the market.
7. With extreme expenditures planned for the next several years in E&P to develop the company's proven reserves and bring them to market, there is virtually no chance of a dividend and a high likelihood of the need to raise additional funds to meet these needs for cash beyond what the production revenues will be able to supply.
8. OGX looks like a moderate risk gamble for the long term if oil prices remain near or above the $100/barrel price. The forecast for U.S. energy independence by 2016 makes this a risky assumption. As the importer of about 20% of the world's available export-market production, a withdrawal by the U.S. from these markets would likely cause a very significant price fall from the current market.
9. The commencement of production sales in third quarter 2012 along with expected large increases in production in 2013 may provide the news needed to arrest share price decline. The significantly lower price/barrel will offset this positive news to at least some degree.
My bottom line on OGX: Treat it like the penny stock it is. An intriguing speculative investment at these prices with far more long term upside potential than down.
Richard
Disclaimer: I am not a licensed securities dealer or advisor. The views here are solely my own and should not be considered or used for investment advice. As always, individuals should determine the suitability for their own situation and perform their own due diligence before making any investment.
Didn't have it on my radar today so I did not see the bid stack, but this looks like some impatient soul could not wait. 50,000 shares traded on that run up. I am still waiting for, I guess we all are, NEO. By the way NEO is exploding looking for a good 3rd and 4th Qtr.
Thanks BVE I have come across some of those figures and will be doing more DD. I do own the stock but looking to add when ever I can grab some around .08 .
I am trying to figure a value on OGXPY seems they could still drill their way to a better price per share. After all this company was launched with great expectations, only now we can recalculate with a lower expectations.
Alivn Snapper is a legit inventeor. He has invented many devices.
https://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Alvin+A.+Snaper%22&gws_rd=ssl
I once invested in one of his inventions, A porous carbon plate battery a very great invention. The only concern I have is he was ripped off by stock hustlers on that invention so he is probably being very careful here. His instant pipe welding invention was swallowed up by the battery company shysters. I'll be watching this one looks like a great invention.
Hi 'Boxsterfan' Just reacting to the volume, that has apparently come out of nowhere. Seeing as NEO is committed to launching our product this quarter I have been looking for volume to pickup. It may be that I have also excited buying because I have posted several references to NEO intention.
After this weekend NEO could start the roll out anytime. The volume may be those, like me, who are waiting for that event and are accumulating or insiders like the last run before Mineta was announced.
Volume Spike today could be leak on Neo's mrkting of the test.
Volume Spike today!
LocWolf The wait may be over! Volume spike today over 4,000,000 shares traded, they are leaky bas**tdrs.
It seems in the case of HRT they would make a new offering including warrants, after the RS, say 1 W for each common. At $9.00 a share few penny buyers will buy but the institutions will feast on HRT and take control simultaneously diluting the original shareholders. They can then take it private or what ever they want.
What matters is it adds $0.02 to my cost/share before the RS but that equates to $1.20/share cost after the RS, therefore I would prefer to avoid the more then 10% extra cost. If the share price stays quite through GDS charge I definitely want increase my share count after that event.
I for one am put off by the $0.02 it will be = to $1.20/ share after the RS of 60/1. I intend to buy after the charge, but I my act if leaks from Nambia drilling produce an up trend in share price.
Reverse split means you divide by the first number in 60 for 1. You give up 60 shares and receive 1 in exchange. If you have 1000 shares divide that number by 60, that is 1000/60 = 16.6666 shares. Your cost is multiplied by 60. If you paid .15 then your cost is .15 x 60 = $9.00 per share.[/b]
This is a good move only if we can produce more oil and or find an elephant field in Nambia.
From NEO prospectus just released.
Hope NEO's desire to launch HDVY's based test this year is realized by summer, they missed on this quarter as far as I am concerned. We need to monitor volume and price for HDVY because these guys always seem to leak and it results in front
running by those in the know.
We are working on developing a proprietary NeoSCORE TM Prostate cancer test that is performed on blood plasma and urine rather than on prostate tissue biopsies. There are two goals for this test, to diagnose the presence of cancer in patients with BPH (Benign prostatic hyperplasia) and to distinguish high-grade from low-grade cancer in patients with prostate cancer. We completed a preliminary patient study in June 2013, and the results were recently published in the Genetic Testing and Molecular Biomarkers journal. In addition, we recently completed a follow up study with additional patient samples which confirmed the published preliminary data. We are also expanding our work to include patient samples from outside the United States. While further validation work needs to be completed, we continue to be excited about the potential for this test. We are planning a limited launch of our NeoSCORE test in the second quarter of 2014 and a full launch later in the year.
In January 2012, we entered into a license agreement with Health Discovery Corporation (“HDC”) to license certain Support Vector Machine / Recursive Feature Elimination technology (“SVM-RFE”). We believe SVM-RFE techniques will allow us to combine and analyze data from genomics, proteomics and digital imaging to develop practical, cost-effective and reliable new assays and other proprietary tests. Using this technology, we believe we will be able to offer a whole line of advanced tests that will help physicians better manage the treatment options for cancer patients. We have prioritized the development of better tests for the diagnosis and prediction of clinical behavior in prostate cancer, pancreatic cancer, breast cancer, leukemia/lymphoma and other solid tumors as part of the License Agreement. We intend to launch a test for prostate cancer in 2014. We are also developing a Cytogenetics Interpretation System using the SVM technology that we believe will result in substantial cost savings and open up the opportunity for sub-licensing revenue in future years.
Forgive the OT but do any of you follow GXPY, Eike Batista's Oil company now in Bankruptcy protection. Creditors have been ling to fund some operations, but have not completely signed off on the Bk I think.
http://investorshub.advfn.com/boards/board.aspx?board_id=16710
So how does the price per GDS relate to a common on the Bovespa? Is it as simple as 0.1375 is 1/2 the common on today trading?
I did not realize that one GDS is equal to 1/2 a share of HRT, am I understanding this news release from HRT
http://www.mzweb.com.br/hrt/web/conteudo_en.asp?idioma=1&conta=44&tipo=32107
I received my proxy, what is the fax number you are talking about?
Hey HDVY'ers
Notice to Shareholders is on the HDC website
April 21, 2014
Dear Fellow Owners of Health Discovery Corporation,
On behalf of the Health Discovery Corporation team, I want to update you on an exciting development.
SVM Capital, LLC ("SVMC"), a joint venture 45% owned by Health Discovery Corporation ("HDC" or the "Company"), has been informed that it achieved a tie for first place in an investment contest for emerging quantitative funds. The contest organizer, BattleFin, announced that the capital sponsor, a major investment fund, is interested in pursuing the winning strategies and moving to due diligence by requesting additional information before a capital commitment is considered.
The contest lasted 11 weeks and there were 20 entrants in SVMC's category. BattleFin audited the daily results of all participants. In terms of return, SVMC placed third, with a return of 6.7% compared to 0.8% for the S&P 500, for an "alpha" of 5.9% for the period. However, after portfolio risk measurements were factored in, SVMC moved into first place. SVMC's lower volatility, zero leverage and proportion of up days (37) to down days (16) were important factors in the risk analysis by the organizer and capital sponsor. Other important factors included SVMC being fully invested every day, maintaining a long/short ratio of 80/20 and rebalancing the portfolio only once during the contest.
The central element in SVMC's performance was the investment algorithm created using the support vector machine technology ("SVM"), which was invented in collaboration between HDC's chief mathematician, Hong Zhang, Ph.D. and the investment domain expert, Mark Moore, Ph.D. The SVM is a supervised machine learning system, a branch of artificial intelligence, which has many applications where vast amounts of complex data must be analyzed. The key to creating the algorithm was adapting the SVM, customarily used in analyzing static data like genes, for use in a dynamic data environment, like stock prices. SVMC believes it may be feasible to construct comparable algorithms for foreign stock markets and other financial markets such as currencies and commodities because price movements in these markets are also subject to a great many complex variables.
SVMC and HDC believe this is an important step in the commercialization of HDC's proprietary technology in a field outside of medical diagnostics, specifically, financial markets. The Company will continue to provide updates regarding additional developments as they become available.
With kind regard on behalf of Health Discovery Corporation,
Kevin Kowbel
Interim Chief Executive Officer and Chairman
GS and MS just may want to take this private, sorry for the negative attitude but I was set to acquire some more as the price went down but this makes me pause. What are the possibilities of a buyout and would it be favorable to us commons?
Problem is they are not yet in the driver's seat in any of their projects. Especially in Alberta; Ecuador seems a little less dependent on Regulators, where a partnership is the catalyst to spark share price movement.
'Oracle Trader' thanks for the heads up on COYN going Profitable.
good question. I have not Investigated that but I am sure the patent has numerous improvements that are essential to its efficient working that extend the basic concept.
Mgmt just has not executed on the HTL Technology the way one would expect, that's for certain, but the there potential does drive the hell out of the share price.
yup, trading pretty good but lets see how much support is here. "Prophet" software predicts $1.08 low, at that point or a little before I'll be loading.